albuterol (Ventolin) vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Ventolin)
Marketed by GlaxoSmithKline
NCT00144846 · Phase 3 · completed
Although the registry describes 80 participants as randomized and double-blind, it lists only a single albuterol arm with no placebo or active comparator. The primary endpoint was safety, and no results are posted, so the study cannot provide a controlled comparison of treatment benefit.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
No aligned efficacy figure on record for this race.
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Ventolin) | Fluticasone propionate/salmeterol (Advair HFA) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT06657066 | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 |
| Trough FEV1, change | 0.1 vs 0.0vs ADVAIR DISKUSNCT0217577114 other results
| —Not posted · NCT00646620 |
| ACQ-5, change | —Not posted · NCT06657066 | —Not posted · NCT00646620 |
| OCS dose reduction | —Not posted · NCT06657066 | —Not posted · NCT00646620 |
Severe exacerbations, annualised rate
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
Trough FEV1, change
- albuterol (Ventolin)
- 0.1 vs 0.0vs ADVAIR DISKUSNCT02175771
14 other results
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.3 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
ACQ-5, change
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
OCS dose reduction
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. albuterol (Ventolin): 7 of 7 rows · Fluticasone propionate/salmeterol (Advair HFA): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol (Ventolin) Rows use multiple source trials | Fluticasone propionate/salmeterol (Advair HFA) Rows use multiple source trials |
|---|---|---|
| FEV1 absolute change · L | 5.96 vs -1.38 placebo La,b,c,d NCT05087693 · Phase 4 · registry result, not featured evidence show 1 more dose6.98 vs -1.38 placebo L NCT05087693 · Phase 4 · registry result, not featured evidence | 0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDb,c,d NCT00452699 · Phase 4 · registry result, not featured evidence |
| Morning PEF Change L/Min absolute change · L/min No placebo or comparator arm | 13.67 L/min @ 24wk100 mg SCe,b,c,d NCT04276233 · Phase 4 · registry result, not featured evidence | 32.9 L/mine,b,c,d NCT00449046 · Phase 3 · registry result, not featured evidence |
| Morning PEF Percent Predicted absolute change · percentage points No placebo or comparator arm | 7.798% (n=194) @ 12wk50/250 mcge,b,c,d NCT00363480 · Phase 4 · registry result, not featured evidence | 12.5% (n=40)e,b,c,d NCT00449046 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 10%100 mg SCf NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 16.7% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 4.8%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 7.7%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 2.2%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.7% NCT01687296 · Phase 3 · registry result, not featured evidence 12.6%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 16%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 18.5%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 18.3%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 16.4%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 5.1%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | —50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 1%100 mg SCf NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence — NCT03924635 · Phase 4 · registry result, not featured evidence · combination —100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 1.8%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence —100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence — NCT01687296 · Phase 3 · registry result, not featured evidence 1.7%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence —160 µg NCT00384189 · Phase 3 · registry result, not featured evidence —80 µg NCT00384189 · Phase 3 · registry result, not featured evidence —40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | —50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3%100 mg SCf NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results0%Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence 0%Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 4.2% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 11%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 2.3% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 0.5%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.1%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence 0% NCT02502734 · Phase 3 · registry result, not featured evidence 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 3.4%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 2.5%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 0.6%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.6%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.3%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence 0%800 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%250 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%58 μg NCT02479412 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0.7%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence 0%800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 0%50/100 mcg/dayg NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mg SCf pyrexia 5% headache 3% oropharyngeal pain 3% NCT04276233 · Phase 4 · registry result, not featured evidence show 34 more results100 mg SC headache 28.3% viral upper respiratory tract infection 16.6% bronchitis 13.1% NCT02654145 · Phase 4 · registry result, not featured evidence asthma 0.1% dry mouth 0.1% dysphonia 0.1% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 50/250 mcg headache 10.4% nasopharyngitis 8.1% bronchitis 5.4% NCT00363480 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · registry result, not featured evidence 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · registry result, not featured evidence 200/62.5/25 mcg nasopharyngitis 32.7% dysgeusia 10.9% eczema 9.1% NCT03184987 · Phase 3 · registry result, not featured evidence 100/10 mcg BID asthma 11% upper respiratory tract infection 9.9% influenza 5.5% NCT02741271 · Phase 3 · registry result, not featured evidence nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence white blood cell count increased 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 200 µg OD headache 12.6% nasopharyngitis 12.6% bronchitis 6.7% NCT01431950 · Phase 3 · registry result, not featured evidence 100 µg OD bronchitis 11.8% nasopharyngitis 11.8% headache 10.1% NCT01431950 · Phase 3 · registry result, not featured evidence 160 µg pharyngitis 5.2% (placebo 4.8%) upper respiratory tract infection 5.2% (placebo 3.4%) nasopharyngitis 4.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 80 µg upper respiratory tract infection 6.4% (placebo 3.4%) pharyngitis 5.8% (placebo 4.8%) nasopharyngitis 3.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 40 µg nasopharyngitis 6.2% (placebo 2.1%) upper respiratory tract infection 5.9% (placebo 3.4%) pharyngitis 4.6% (placebo 4.8%) NCT00384189 · Phase 3 · registry result, not featured evidence 800 μg nasopharyngitis 11.8% (placebo 15.4%) diarrhoea 8.8% (placebo 0%) headache 5.9% (placebo 0%) NCT02479412 · Phase 2 · registry result, not featured evidence 250 μg headache 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 15.4%) asthma 2.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 58 μg nasopharyngitis 11.8% (placebo 15.4%) gastroenteritis 8.8% (placebo 0%) cough 5.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence 800 ug catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence | 50/100 mcg/dayg upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eTrial phases differ: Phase 4 versus Phase 3.
- fPopulation comparability has not been reviewed for 31 of these studies.
- gPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol (Ventolin)
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 38 further endpoints in the CSV export.
Fluticasone propionate/salmeterol (Advair HFA)
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Ventolin)'s landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape